Safety and Pregnancy Outcomes in Thrombocythemia Patients Exposed to XAGRID® (Anagrelide Hydrochloride) Compared to Other Treatments
A Non-Interventional, Post Authorisation Safety Study, to Continuously Monitor Safety and Pregnancy Outcomes in a Cohort of At-Risk Essential Thrombocythaemia (ET) Subjects Exposed to Xagrid Compared to Other Conventional Cytoreductive Treatments
Sponsor: Shire
A observational or N/A phase clinical study on Thrombocythemia, Essential, this trial is completed. The trial is conducted by Shire and has accumulated 11 data snapshots since 2005. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
11 versions recorded-
Sep 2025 — Present [monthly]
Completed
-
Sep 2024 — Sep 2025 [monthly]
Completed
-
Jul 2024 — Sep 2024 [monthly]
Completed
-
Dec 2021 — Jul 2024 [monthly]
Completed
-
Sep 2021 — Dec 2021 [monthly]
Completed
▶ Show 6 earlier versions
-
Jan 2021 — Sep 2021 [monthly]
Completed
-
Sep 2020 — Jan 2021 [monthly]
Completed
-
Jun 2018 — Sep 2020 [monthly]
Completed
-
Apr 2018 — Jun 2018 [monthly]
Completed
Phase: NA → None
-
Feb 2017 — Apr 2018 [monthly]
Completed NA
-
Jan 2017 — Feb 2017 [monthly]
Completed NA
First recorded
May 2005
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Shire
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Amsterdam, Netherlands , Ancona, Italy , Arezzo, Italy , Argenteuil, France , Aschaffenburg, Germany , Athens, Greece , Augsburg, Germany , Barakaldo, Spain , Barcelona, Spain , Bari, Italy and 118 more locations